A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
At a glance
- Drugs TAK 659 (Primary) ; Venetoclax
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 29 Jan 2018 Planned initiation date changed from 29 Nov 2017 to 15 Feb 2018.
- 04 Dec 2017 New trial record